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Abstract 
An interesting inference drawn by some Covid-19 epidemiological models is that there exists a 
proportion of the population who are not susceptible to infection – even at the start of the current 
pandemic. This paper introduces a model of the immune response to a virus. This is based upon the 
same sort of mean-field dynamics as used in epidemiology. However, in place of the location, clinical 
status, and other attributes of people in an epidemiological model, we consider the state of a virus, B 
and T-lymphocytes, and the antibodies they generate. Our aim is to formalise some key hypotheses as 
to the mechanism of resistance. We present a series of simple simulations illustrating changes to the 
dynamics of the immune response under these hypotheses. These include attenuated viral cell entry, 
pre-existing cross-reactive humoral (antibody-mediated) immunity, and enhanced T-cell dependent 
immunity. Finally, we illustrate the potential application of this sort of model by illustrating variational 
inversion (using simulated data) of this model to illustrate its use in testing hypotheses. In principle, 
this furnishes a fast and efficient immunological assay – based on sequential serology – that provides 
a (i) quantitative measure of latent immunological responses and  (ii) a Bayes optimal classification of 
the different kinds of immunological response (c.f., glucose tolerance tests used to test for insulin 
resistance). This may be especially useful in assessing SARS-CoV-2 vaccines. 
Keywords:  Dynamic causal modelling; Variational Bayes; Covid-19; Immunity; Resistance; 
Antibodies; T-cells 
 
1 – Introduction 
Recently, we produced a series of technical reports applying dynamic causal modelling (DCM) to 
epidemiological data to illustrate how this might be applied to understanding the Covid-19 pandemic 
[1-4]. This is an approach developed in neuroimaging research that attempts to find the best 
explanations for observed timeseries data [5]. An interesting outcome of this work is that the best 
explanations of data from the current pandemic appeal to there being sizeable portions of the population 
who either are not susceptible to the virus, or who have such a mild course of illness that they are 
unlikely to pass it on. The term ‘immunological dark matter’ has found some media purchase1 in 
describing this finding. However, the idea behind this phrase is simple. The implication is that one or 
more unmeasured variables confer a degree of non-susceptibility or resistance to severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). This may be partly due to demographic factors, 
such as geographical isolation or shielding. In addition, it is likely that heterogeneity in the immune 
response people mount to the virus contributes to this [6-9]. 
 
1 https://www.theguardian.com/world/2020/may/31/covid-19-expert-karl-friston-germany-may-have-more-
immunological-dark-matter 
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This raises the question as to what the differences in immunity may be and how we could test this. In 
this paper, we formalise some of the hypotheses raised as to the immunological factors conferring 
resistance. We have no pretensions of answering this question – which almost certainly has several 
different concurrently correct answers – but hope to illustrate how the variational methods used in the 
epidemiological DCM could be repurposed to test hypotheses about the causes of resistance. This may 
be particularly salient in the setting of vaccine trials, in which a great deal of immunological data may 
be collected following a timed exposure to viral antigens – and in which the immunity conferred by a 
vaccine may transcend purely antibody mediated immunity [10,11], which appears to have a relatively 
low prevalence [12]. As such, the model presented here is designed to include antibody mediated 
immunity, but also to allow for alternative (e.g., T-cell mediated) forms of resistance. The use of 
variational inference procedures in this setting allows for fast and efficient inferences at the individual 
level, quantification of the uncertainty surrounding these estimates, and hypothesis testing as to the best 
explanation for individual serology results. 
The DCM approach relies upon the notion of a generative or forward model that generates measurable 
data. The idea here is that, by adjusting the parameters of this model, we can find the parameter 
configurations that minimise any discrepancy between synthetic and measured data, subject to prior 
beliefs about the plausibility of those configurations. Practically, this proceeds using variational 
Bayesian inference [13,14]. We make use of a variational Laplace procedure [15] that maximises a 
lower bound on the marginal likelihood (or model evidence) of data. The bound is known variously as 
an evidence lower bound (ELBO) or negative free energy. The benefit of the forward modelling 
approach is that it appeals directly to the mechanisms that generate data. We are interested in measures 
of immunity that include the viral load, antibody levels, and T-cell responses (as indicated by interferon-
γ secretion by CD4 and CD8 positive T-cells). This approach allows us to make inferences about 
immunity that can arise from interacting and multifactored immune responses. 
In the following sections, we first set out a generative model of immune responses. Like many 
epidemiological models [16] – and existing immunological models [17] – this is a compartment model. 
This means each component of the immune system exists in one of several alternative states that they 
may transition between. As in the location, infection, symptom, testing (LIST) DCM [1], our generative 
model appeals to different factors, corresponding to different arms of the immune system. After 
introducing this model, we set out formalisations of hypotheses as to the causes of resistance. We then 
illustrate the fitting of this model to (synthetic) data highlighting how these alternative hypotheses could 
be tested for a specific resistant individual. Finally, we discuss the potential implications of this 
approach – including the importance of not overinterpreting negative antibody tests [18]. 
 
2 – A mean-field model of the immune response 
The approach we pursue here is based upon a mean-field approximation that separates an immune 
response into five different factors or modules [19-21]. These are the antibodies (which subdivide into 
IgG and IgM types), B-cells, T-cells, and the virus itself. Figure 1 summarises the key aspects of the 
model dynamics. Each factor has a number of levels, with some probability assigned to each level. The 
dynamics of the model are formulated in terms of the move of probability mass between these levels. 
For example, antibody synthesis is the process of moving probability mass from the ‘absent’ level to 
the neutralising or non-neutralising antibody states. The dashed arrows between factors in Figure 1 
show the direction of influence of factors on one another. We will unpack the model by going through 
these, starting from the reciprocal influence of the virus on T-cells, followed by T-cell mediation of the 
B-cell response. We then outline the interaction between B-cells and the virus, B-cells and antibodies, 
and antibodies and virus. 
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Figure 1 – The generative model. This schematic sets out the five factors of the generative 
model and the data modalities they generate. There are two antibody factors (IgG and IgM). For 
these factors, the absent antibody can become either neutralising or non-neutralising, and each of 
these can decay back to being absent. Similarly, the T-cell factor allows for transitions between 
being naïve to either CD4+ or CD8+ cells. These decay back to naïve, under the assumption that 
the production of naïve T-cells occurs at approximately the same rate as the death rate of 
specialised T-cells to maintain a roughly constant T-cell population.  The viral dynamics include 
an absent state, which transitions to being extracellular depending upon the amount of 
intracellular virus. This represents the intracellular replication and shedding of virus into the 
extracellular compartment. The extracellular virus then moves into the intracellular compartment 
– where further replication and shedding can take place. The B-cell factor is slightly more 
complex as this includes five different levels. Naïve B-cells become either IgM plasma cells or 
immature memory cells. Immature (I) memory cells develop into mature (M) memory cells, 
which themselves can become IgG plasma cells. Mature memory cells and plasma cells decay 
into naïve cells over time. The dashed connections between factors with round arrows express 
the directed influences between factors, as described in more detail in the main text. The influence 
of one factor over another is to increase or decrease the rates of transition between selected levels 
of that factor. The three numbers in black circles indicate the parameters we will manipulate to 
augment or attenuate the immune response. 
 
The influence of the virus on the T-cells is to increase the rate at which naïve T-cells specialise [22]. 
Some proportion (θCD4) of naïve cells transition to being CD4+ cells each hour, scaled by the probability 
of the virus being extracellular. Similarly, some proportion (θCD8) of naïve cells transition to being 
CD8+ cells each hour, scaled by the probability of the virus being intracellular. Our definition of the 
term ‘naïve’ T-cells is deliberately broad, to account for any T-cell that has the potential to become an 
activated CD4+ or CD8+ cell selective for a viral antigen. This might include CD4+ or CD8+ cells that 
have not become activated or started to secrete cytokines like interferon-γ (INF-γ), in addition to cells 
that have yet to express CD4 or CD8 surface markers [23]. 
The influence of the T-cells on the viral factor are as follows. In proportion to the number of CD4+ T-
cells, the extracellular virus moves to the absent state. This stands in for the effect of CD4+ cell 
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mediated activation of parts of the innate immune system – for example, the activation of macrophages 
that phagocytose and kill pathogens [24]. Responses mediated by these cells are known to have a role 
in influenza virus and coronavirus infections [25,26]. The CD8+ cell causes a move of intracellular 
virus to the absent state. This represents the cytotoxic activity of these cells, prompting apoptosis of 
infected cells [27]. The proportion moving to the absent state is given by the probability of a T-cell 
being a CD8+ cell multiplied by 0.5(θTCP + θdpi), where the first parameter deals with the effect of the 
cytotoxic (CD8+) cell on the pathogen, and the second is the decay of the intracellular pathogen due to 
T-cell independent mechanisms. The latter is invariant to the T-cell state. We have not specified the 
mechanism of decay of intracellular and extracellular virus here, such that these variables could 
encompass innate immunity, non-functional viral mutations, and host cell death [28,29]. 
In addition to their direct effects on the virus, the T-cells promote a B-cell response [30]. Specifically, 
in the presence of CD4+ cells, naïve B-cells become (immature) memory cells [31] or IgM-secreting 
plasma cells. The proportion of B-cells specialising is proportional to the number of CD4+ cells, with 
proportionality constant θBC. The proportion of specialising B-cells becoming memory cells is 
parameterised as θBCm. The decay of the (IgM and IgG) plasma cells is parameterised as θdpB and is 
independent of T-cells. Similarly, there is a constant move of immature memory cells into the mature 
memory cell state (θmba) and a decay of mature memory cells (θdmB) – neither of which depends upon 
the T-cells or presence of pathogen. The viral influence on B-cells is to cause the mature memory cells 
to transition to the IgG plasma cell state (parameterised by θBmp) [32]. 
The B-cell factor exerts an influence over the antibody factors, with IgM plasma cells leading to a move 
from absent to neutralising or non-neutralising proportional to θpAb (where the proportion that are 
neutralising is given by θnAb) in the IgM antibody factor, and IgG plasma cells leading to the equivalent 
dynamics in the IgG antibody factor. Regardless of the B-cell factor, antibodies decay to the absent 
state with rate parameterised by θdAb for IgM antibodies and the slower θdAbG for IgG antibodies. Finally, 
the antibodies exert an influence over the viral population, with extracellular virus moving to the absent 
state in proportion to the antibodies in the neutralising state. The overall structure of these dynamics is 
given in Equation 1, where the Δτ used for the simulations is one hour. 
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Each p is a vector of probabilities, with superscripts indexing the factor that these probabilities pertain 
to. T is a transition matrix that updates these probabilities for a given time interval. The order of states 
shown in these probability vectors are as follows. The viral states are absent, extracellular, and 
intracellular. The T-cell states are naïve, CD4+, and CD8+. The B-cell states are naïve, plasma (IgM), 
immature memory, mature memory, plasma (IgG). Both sets of antibody states are absent, non-
neutralising, neutralising. Note that a very small amount of virus can be present in the extracellular 
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space at the start, and that a small proportion of B-cells exist in the mature memory B-cell state at the 
start. 
For a generative model to be useful, it should be able to generate data of the sort that can be measured. 
The model in Figure 1 generates antibody levels, extracellular viral load, and the proportion of activated 
CD4+ [33,34] and CD8+ cells [7]. These are generated by summing the proportions of neutralising and 
non-neutralising antibodies, and taking the proportions of the other variables, and then scaling these by 
the maximum values we expect them to take. The scaling factors include a fixed and a random 
component. The fixed component determines the maximum value when the random component takes 
its prior expected value of 1. The random variables are θ-parameters as detailed in Table 1, meaning 
these could be estimated from measured data. These measurements are relative to some baseline which 
is likely to be zero for viral load but may be higher for the other variables. IFN-γ secretion is generally 
accepted as a measure of activation of CD4+ and CD8+ cells [35]. Evidence from H7N9 influenza virus 
infections suggests that recovery from the viral infection is positively associated with IFN-γ secretion 
by CD4+ and CD8+ cells [35]; emphasising the importance of these ‘activated’ cells as measures of the 
immune response. Put formally, the process generating data is as follows: 
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Each of these data modalities (y) are multiplied by a constant and a scaling parameter, which may be 
estimated during model inversion. By inversion, we mean the process of inferring the parameters that 
caused the data. We do not assume data are generated every hour (the rate of update of latent dynamics). 
Instead, we assume measurements are only available every 24 hours. This is perhaps a little optimistic, 
but the model is formulated such that the measurement timings can be arbitrarily set, to account for 
when measurements are available. Table 1 provides the parameters used in the simulations that follow. 
It is important to emphasise that the priors chosen here are largely heuristic. These will vary with 
infection between different organisms, and between hosts. This means the simulations that follow 
should not be taken as making any comment on any specific infection. Ideally these would be estimated 
from empirical data. In the absence of these data, we have selected parameters such that the relative 
timing of each response is broadly consistent with that observed in biology, and that is consistent with 
a self-limiting infection that is largely cleared within about three weeks. We discuss this consistency in 
relation to the time course of measurements during SARS-CoV-2 infections below. While this allows 
us to illustrate general principles, these illustrations should be taken as qualitative as opposed to 
quantitative. 
 
Table 1 – Priors for normal immune response (log parameters) 
Parameter Symbol Expectation Variance 
Scaling for initial immunity ln n   -2 1 
Scaling for initial viral load ln m  0 1/256 
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Decay of IgM antibodies ln dAb  -6 1/1024 
Decay of IgG antibodies ln dAbG  -8 1/1024 
Production of antibodies by plasma cells ln pAb  0 1/1024 
Proportion of antibodies that are neutralising ln nAb  -1 1/1024 
Decay of plasma B-cells ln dpB  -2 1/1024 
Decay of memory B-cells ln dmB  -32 1/1024 
Activation of memory B-cells ln mba  -4 1/1024 
Proportion of mature memory cells becoming plasma cells 
in presence of infection 
ln Bmp  -1/2 1/1024 
Specialisation of naïve B-cells in the presence of CD4+ T-
cells 
ln BC  -3 1/1024 
Proportion of B-cells specialising as memory cells ln BCm  -1 1/1024 
Decay of CD4+ cells 
4ln dT  -4 1/1024 
Decay of CD8+ cells 
8ln dT  -5 1/1024 
Production of CD4+ cells in presence of extracellular 
pathogen 
4ln CD  -3 1/1024 
Production of CD8+ cells in presence of intracellular 
pathogen 
8ln CD  -3 1/1024 
Neutralisation of intracellular pathogen by T-cell mediated 
apoptosis 
ln TCP  -2 7/32 
Neutralisation of extracellular pathogen by antibody 
independent CD4+ mechanisms 
4ln T P  -8 1/1024 
Viral entry into cells ln int  -2 1/16 
Viral shedding into extracellular space (absorbing 
replication rate) 
ln ext  -1 1/1024 
Decay of extracellular pathogen (independent of adaptive 
immunity) 
ln dpe  -2 1/1024 
Decay of intracellular pathogen (independent of adaptive 
immunity) 
ln dpi  -2 1/1024 
Scaling of antibody titre measures ln Abm  0 1/256 
Scaling of viral load measures ln VLm  0 1/256 
Scaling of IFN-γ T-cell assays ln IFN  0 1/256 
 
While the variances in Table 1 may seem very small, it is important to remember that we are working 
with log parameters – so small changes can result in large changes once exponentiated. We will see the 
large confidence intervals in subsequent figures reflecting this. Secondly, many of the parameters we 
deal with play the role of probabilities, which means tight priors are required so that these parameters 
do not exceed a sum total of one2. We use these tighter priors for simulation purposes; we relax the 
variances later, when demonstrating model fitting. It is worth drawing attention to the variances for the 
initial immunity, the viral cell entry, and the T-cell mediated apoptosis parameters. The variances for 
these are chosen to be very wide as these are the key parameters we will be varying later. Specifically, 
 
2 This highlights a trade-off in our decision to use normally distributed priors. An alternative would be to use 
Dirichlet distributed priors, which ensure summation to one. However, the flexibility afforded by the use of 
normal distributions, and the simplicity of variational inference under a Laplace assumption, favours the use of 
normally distributed log parameters.  
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these are chosen such that the modifications we will make to these parameters amount to a change of 
approximately one standard deviation each3. 
Figure 2 illustrates an immune response generated from the prior expectations in Table 1. Here we see 
the rapid increase in viral load as the initial extracellular virus enters the cells enabling intracellular 
replication and shedding into the extracellular space. As the extracellular viral load increases, this 
initiates a helper (CD4+) T-cell response that increases the number of plasma B-cells and causes a rapid 
increase in antibody levels. Later peaks are seen in the populations of cytotoxic (CD8+) T-cells and 
memory B-cells. As the viral load is suppressed, the immune cell populations decay, with the exception 
of the mature memory cells. This is because, in the presence of the virus, mature memory cells rapidly 
transition into plasma cells. This means they are the only cell type to decrease in number during the 
initial phase of the infection but increase later on from the immature memory cells acquired during the 
infection. In the antibody response plot, note the early IgM response, followed by a slower but more 
sustained IgG response. This reflects the characteristic role of these isotypes in fast and long-lasting 
immunity, respectively. 
Figure 2 also illustrates some face validity of this approach in relation to the emerging data on the 
immune response in Covid-19. The time-course and magnitude of the antibody response is broadly 
consistent with data suggesting peak antibody titres in the region of about 26 [36] (measured as 
chemiluminescence levels relative to some cut-off), consistent with the upper bound approaching 60 in 
the antibody plot in Figure 2, and an increase in IgG relative to IgM over time, both plateauing at around 
day 20 following symptom onset. This is slightly earlier than in our simulation but may reflect the time 
it takes for the viral load to reach a level that causes symptoms. For ease of comparison with empirical 
reports we plot the viral load (yVL), generated according to Equation 2, after transforming into the cycle 
threshold for detection using a polymerase chain reaction (PCR). See the legend of Figure 2 for details. 
The viral load appears to decline from a cycle threshold (Ct) of about 30 to 40 over the space of about 
10 days [37], consistent with the lower left plot in Figure 2. In the lower right plot, the percentage of 
CD4+ and CD8+ cells producing IFN-γ peaks at around 0.2 per hundred cells (with upper limit around 
0.5), consistent with the kinds of ranges reported in some empirical studies [38]. While these 
comparisons are heuristic and will almost certainly vary with laboratory equipment and local 
measurement procedures, they illustrate face validity in the sense that the data generated broadly 
resemble measurable data. 
 
3 This accounts for the variances of 1, 7/32, and 1/16, which are much larger than those for other priors. The 
reason for this will become more obvious in Section 4. Briefly, they are chosen to avoid biasing our model 
fitting towards one phenotype or another. 
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Figure 2 – A synthetic immune response. The upper left plot shows the latent variables in terms 
of the different types of antibody. This distinguishes between the faster IgM response, and the 
more prolonged IgG response, and between the neutralising and non-neutralising variants of 
each. The upper right plot shows the cellular latent variables, with an initial increase in the 
activated T-cell proportions that leads to a later increase in plasma and memory cells, with a 
persistent memory response developing. The middle left plot shows the viral states, subdivided 
into intracellular and extracellular components. The middle right plot shows the total antibody 
level, including both neutralising and non-neutralising. The lower left plot shows the viral load 
in terms of the ‘threshold cycle’ (Ct) which indicates the number of cycles of polymerase chain 
reaction (PCR) required before the viral nucleic acids are detectable. A greater number of cycles 
indicates a greater dilution (i.e., a smaller concentration). To generate these data, we took the 
negative log [39,40] of y(τ)VL, scaled it by a factor of 4, and added a constant 50 – under the 
assumption that more than 40 cycles implies a negligible viral concentration, based on 
fluorescence amplification results for a typical qPCR run [41]. These scale factors and constants 
could in principle be fit to empirical data. Here they are used only for the plotting and have no 
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influence on model inversion. Finally, the lower right plot shows the proportion of CD4+ and 
CD8+ cells releasing IFN-γ.  
 
3 – Routes to resistance 
Figure 3 provides an overview of the mechanisms for resistance that we address here. This is not 
exhaustive but highlights three important ways in which the immune system might vary between 
individuals. We will take each of these in turn and demonstrate the influence they have on the dynamics 
of the immune response under our model. Figure 4 offers a comparison between the dynamics of latent 
states under each manipulation for ease of comparison between the time course of antibody, cellular, 
and viral responses. The same plots will be shown in subsequent figures, which we will unpack in detail. 
 
 
Figure 3 – Mechanisms of resistance. In what follows, we will illustrate various modifications 
to the model simulated in Figure 2, by changing model priors. The graphics in this figure provide 
an overview of the three manipulations we will pursue in terms of the associated biological 
mechanisms. These mechanisms are reduced viral entry into host cells, pre-existing memory B-
cells, and enhanced T-cell dependent killing of infected cells. 
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Figure 4 – Latent variables. This figure takes the latent variable plots from Figure 2 and 
supplements them with those that will appear in Figures 5-7. The format is as described in Figure 
2. We will unpack the details of these plots as they are introduced in subsequent figures. 
However, the highlights are (i) the attenuation of peak viral load in the second to fourth row of 
plots, relative to the first row, (ii) the smaller antibody response required to suppress the infection 
in the second and fourth rows of plots, (iii) the earlier peak in IgG plasma cells and antibodies in 
the third row of plots. The key message from this figure is that there are several different 
dimensions along which immune responses may vary, with consequences for viral suppression. 
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The first route to resistance is a reduced capacity for viral entry into cells. In the context of SARS-CoV-
2, this could be due to polymorphisms in the cell surface ACE-receptors targeted by the virus [42] – or 
to age-dependent differences in expression [43]. In terms of the model outlined above, this is an 
attenuation of the rate at which extracellular virus becomes intracellular. Specifically, we changed the 
expectation of lnθint from -2 to -2.2. Figure 5 shows a simulation of this scenario. Given that viral 
reproduction occurs in the intracellular compartment, slower entry into this compartment leads to a 
failure to increase the viral population. This leads to a viral load that is lower at its peak than in Figure 
2 – possibly suggesting people with this phenotype are less infectious (note the differences in y-axis 
scales between Figures 2 and 5). However, the most obvious difference between Figures 2 and 5 is the 
magnitude of the immune response required to clear the virus. In Figure 5, we see a much smaller 
response, and might anticipate a failure to detect antibodies post-infection in such individuals. In 
addition, a smaller immune response might mean fewer symptoms during the course of the infection. 
The second route is pre-existing cross-reactivity of antibodies, which we simulate through assuming a 
larger population of memory cells capable of rapid specialisation into plasma cells that target the virus. 
By cross-reactivity, we mean that antibodies developed to some previous infection may also be effective 
against the current infection [8,44]. Specifically, we formalise this by increasing lnθn from -2 to 2. 
Figure 6 illustrates the rapid drop in mature memory cell populations as they become IgG plasma cells, 
and the resulting increase in IgG antibodies. Note that the plasma IgG cells never reach the same level 
as the original memory cell population. This is because their rate of decay is considerably faster than 
that of memory cells. The key differences between this simulation and that reported in Figure 2 are the 
earlier and more dramatic IgG response, which now precedes the attenuated IgM response, and the 
decrease in peak viral load. Longitudinal studies of these antibodies in Covid-19 show this pattern in 
patients with low severity disease, compared to an earlier IgM response (as in Figure 2) in more severe 
disease [45].  
Third, the response could be mediated by antibody independent T-cell mechanisms [7,46] that suppress 
the virus before the viral load is sufficient to promote plasma cell proliferation. A similar hypothesis 
could be advanced for a purely innate immune response, by increasing the rate of decay of the virus 
independently of the states of the other three factors. Cell-mediated immunity is well recognised to vary 
with age [47,48] and could account for the relative resistance of younger members of the population. 
Suggestive evidence in favour of the relevance of CD8+ dependent mechanisms comes from genomic 
studies that have identified loci associated with lung CD8+ cells as differing between those with severe 
Covid-19 and the control population (people without a known diagnosis of Covid-19) [49]. Some T-
cells in the respiratory system are thought to have a role in immunological memory, which may be 
independent of B-cell memory systems [50,51]. This is one possible interpretation for a more vigorous 
T-cell response in some people, whose T-cells have encountered similar antigens in the past. There are 
also emerging data suggesting SARS-CoV-2 itself induces a memory T-cell response [38], in addition 
to there being T-cells reactive to viral antigens in people who have yet to be exposed [7].  Although we 
have formalised this in terms of CD8+ responses (by increasing lnθTCP from -2 to -1/8), there is also 
evidence in favour of a role for CD4+ responses in rapid suppression of influenza viruses in some 
individuals – something that has been proposed as a mechanism for the difference in disease severity 
between successive infections in individuals [26]. Figure 7 shows the influence of increasing the 
effectiveness of T-cell dependent killing on the immune response, which appears to reduce viral load 
and dampen and prolong antibody and cell mediated responses. 
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Figure 5 – Attenuating viral entry into cells. This figure uses the same layout as Figure 2. Here, 
the proportion of extracellular virus entering the intracellular compartment per hour has been 
decreased, remembering that the production of extracellular virus depends upon there being 
intracellular virus that can use the cellular machinery to manufacture and secrete new virus 
particles. Decreasing the rate of cell entry therefore slows the growth of the viral population, 
leading to a smaller peak with a smaller immune response required to suppress the infection. Note 
the decrease in antibody titre, which might mean that people exhibiting this immune phenotype 
may not have detectable antibodies in serological testing post-infection. 
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Figure 6 – Pre-existing immunity. This figure uses the same layout as Figure 2. Here, the 
proportion of mature memory cells at the start of the infection has been increased, to simulate the 
scenario that immunological memory may have been instantiated by exposure to related viruses 
in the past. Note the rapid increase in the IgG response, in contrast to the early IgM response we 
saw in Figure 2. Like in Figure 5, the virus is suppressed and never reaches as high a viral load 
as in Figure 2. However, here we see a sustained increase in serum immunoglobulin in the latent 
(upper left) and measurable (middle right) antibody response plots. This pattern of response 
might be associated with a very mild illness, not prompting testing for the virus (or possibly even 
an undetectable viral load on being tested) but would be associated with positive serological tests 
later on. 
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Figure 7 – Cell mediated immunity. This figure uses the same layout as Figure 2. The scenario 
simulated here is one in which the proportion of intracellular virus destroyed through T-cell 
mediated mechanisms is increased. This could be interpreted as a memory T-cell mediated 
response. Here we see a smaller viral load and a flattened antibody response.  
 
Clearly there are many other phenotypes we could have considered [52]. These could include mixtures 
of the above, or more extreme values of the parameters. For example, if we reduce the viral cell entry 
sufficiently, the viral load never rises at all, but immediately decays to zero – with a negligible immune 
response. In contrast, if we sufficiently attenuate the immune response (e.g., by reducing activation of 
T and B cells), the viral load increases to its carrying capacity and stays there. There are a range of other 
intermediate scenarios, like a small but persistent viral load that is never fully suppressed (perhaps more 
consistent with some hepatitis viruses [53]), or even second waves (without reinfection) if the antibodies 
decay sufficiently quickly. These parameter settings might be more appropriate in modelling viruses 
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with latent phases that reactivate when immunity decays. For example, varicella zoster virus causes 
chickenpox before being suppressed, but can re-emerge later as shingles [54].  
 
4 – Immunological phenotyping 
In this section, we attempt to do two things. The first is to find out whether the three phenotypes 
identified above (lower proportion of extracellular virus entering cells; higher proportion of mature 
memory cells on infection; and higher proportion of intracellular virus destroyed through T-cell 
mediation) may be disambiguated from one another based upon the data that we assume they generate. 
This rests on the idea that an individual has one, rather than a mixture, of these phenotypes. However, 
it would be simple to extend this analysis by specifying additional phenotypes that comprise mixtures 
of those outlined in Section 3. The second aim in this section is to ask whether we could identify 
interactions between demographic factors – such as whether or not someone has received a Bacillus 
Calmette-Guérin (BCG) vaccine – and parameters of the models above – for example, T-cell dependent 
killing of pathogen [55]. We will use the BCG hypothesis, that T-cell dependent killing is enhanced by 
the BCG vaccine, as an example to aid intuition. This is not intended to endorse or refute this hypothesis, 
but to show how DCM may be used to formulate and test hypotheses of this sort. 
For the first of these aims, we took the outputs of the above simulations assuming one measurement per 
day for the first three weeks, added univariate random fluctuations with a variance of 1/8 to the square 
roots of the data. We then fit each synthetic dataset – comprising daily measurements of the viral load, 
antibody levels, and proportion T-cells releasing of IFN-γ – to the model with the prior expectations in 
Table 1, but with variances multiplied by 16. Model fitting here means finding approximate posterior 
probabilities Q that maximise a lower bound on model evidence (the marginal likelihood of the data 
given the model): 
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In Equation 3, θ are the parameters, y the data, and m is the model. Maximisation of the model evidence 
ensures an optimal trade-off between the accuracy with which data can be explained and the simplicity 
of that explanation – penalising excessively complex explanations. This maximisation was achieved 
using a standard software routine (spm_nlsi_GN.m4). We then used Bayesian model reduction (BMR) 
– a method for efficient post-hoc model comparison [56,57] – to evaluate the relative evidence for 
alternative models with the prior expectations set out in Table 1, with expectations modified as 
described in Section 3. The reason for the more uncertain priors used during fitting of the full model is 
that BMR treats each alternative model as a reduced version of the ‘full’ model. By setting the variances 
in the full model to be much larger than those in any of the reduced models, we ensured that the 
expectations of the reduced priors would be plausible under the full prior distribution. The principle 
that underwrites BMR is that, when only the priors differ between models, the relative evidence of two 
models is given by the following equation – which only requires inversion of one of the two: 
 
 
4 Freely available as part of the SPM12 package at https://www.fil.ion.ucl.ac.uk/spm/software/spm12/  
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The graphic on the left of Figure 8 shows a confusion matrix, whose rows correspond to the model used 
to fit the data, and whose columns correspond to the model that generated those data. Each element of 
the matrix is shaded by the posterior probability of the model given the data, with white indicating a 
probability of one and black zero. Posterior probabilities are obtained through using a softmax 
(normalised exponential) operator on the log model evidence given by BMR for each column. The 
lighter shading along the diagonal elements compared to the off-diagonal elements in the same column 
implies it is possible to recover the mechanism generating observed timeseries – albeit with varying 
degrees of confidence. The implication of this is that, in principle, it is possible to use empirical data to 
assign individuals to the immunological phenotype that best explains their measured serology.  
 
 
Figure 8 – Immunological phenotyping. This figure illustrates two ways in which this 
modelling approach may be used. The left panel shows a confusion matrix that plots the posterior 
probability of each model given each dataset. White indicates a probability of one, while black 
indicates a probability of zero, with grey being intermediate values. The diagonal elements of 
this matrix represent the posterior probability of a model given the data that it was used to 
generate, and these probabilities are reassuringly higher than those for other models. The models 
are ordered such that 1-4 correspond to The rows of Figure 4. The idea here is that alternative 
hypotheses may be posed to data from an individual’s immune response, and that we hope to be 
able to recover which model best represents that individual’s immune response. The second use 
of this approach is shown on the right, where a synthetic group level analysis has been used to 
test hypotheses about the role of demographic factors (e.g., whether or not someone has received 
a BCG vaccine) on parameters of the model (e.g., the cytotoxic T-cell response). The plots 
labelled log-posterior and model posterior show the probability associated with group level 
models that include various combinations of constant (β0) and linear (β1) effects on the θTCP 
parameter. The constant effect is the expected value for all those without a BCG vaccine, while 
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the linear effect is the amount added to the log expected parameter when someone has had this 
vaccine. The presence or absence of these parameters (where absence means set to zero) for each 
model is shown in the model space plot with white indicating presence and black absence. The 
posterior plot shows the probability of each parameter being present. The MAP plot shows 
maximum a posteriori estimates for the model including all parameters (with 90% credible 
intervals) while the MAP (reduced) plot shows these when averaged under the relative probability 
of each reduced model. 
 
The plots shown on the right of Figure 8 illustrate an alternative application of this approach to answer 
a question at the level of between subject effects. Here, we generated 32 immune responses, as if from 
32 different subjects. Each subject was assigned to the BCG group or the unvaccinated group with a 
probability of ½. The priors were all as in Table 1, except for the θTCP parameter whose expectation was 
sampled from a normal distribution for each individual. The mean of this distribution was set at -2, with 
2 added for those with a BCG. In this synthetic example, this implies the BCG vaccine confers some T-
cell mediated immunity. We then fit each of the 32 synthetic datasets using the priors of Table 1, and 
used a parametric empirical Bayes scheme (spm_dcm_peb.m) to estimate the parameters of a second 
level linear model [56,58], which predicted the θTCP parameter based upon the presence or absence of 
the BCG. This second level model has the form: 
 
0 1ln
i i i
TCP X   = + +           (5) 
 
Here, the superscript i indicates the subject, the β0 is a constant value for those with no BCG, and the 
β1 is the effect of having had the BCG. X
i is one if a subject has had the BCG, and zero otherwise. The 
ω term indicates normally distributed, zero-mean, fluctuations. The plots on the right of Figure 8 show 
that a model in which both β parameters are allowed to be non-zero provides the best explanation for 
the synthetic data. Furthermore, the maximum a posteriori estimates are consistent with the -2 for the 
absence of a BCG and the positive effect associated with this vaccine used to generate the synthetic 
data.  This illustrates that, if it were true that the BCG vaccine enhances T-cell-mediated immunity, we 
could recover this information using this sort of analysis. Again, this is not to suggest that this 
hypothesis is correct (or incorrect). Instead, our aim is to show that it could be demonstrated if it were 
true. 
 
5 – Discussion 
How does this sort of modelling relate to epidemiology? Drawing from theoretical neurobiology, we 
could think of immunological and epidemiological models as simply different levels of parcellation – 
just as we have the option of parcellating the brain on the level of regions or on the level of networks, 
depending upon the question at hand. Recent work [59] in this direction makes use of renormalisation 
groups [60] to translate between these scales. In brief, this works by identifying functional units at small 
spatial scales (e.g., individuals at different stages of viral exposure) and extracting low dimensional 
summaries of their dynamics based upon the system’s Jacobian. These are typically along the direction 
of the eigenvectors with the smallest negative eigenvalues – effectively omitting dynamics that dissipate 
very quickly [61]. This procedure may be applied recursively to move to high level summaries in a 
population (e.g., the proportion of individuals at each stage). A key feature of these analyses is that 
increases in spatial scales are accompanied by slower dynamics. Consistent with this, the course of 
infection for an individual – lasting for a period of a few days to weeks – is much shorter than that of 
an epidemic (a few months) or a pandemic (potentially years). This method affords the possibility of 
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using inferences drawn at the level of individual immune responses to nuance models used at an 
epidemiological level. 
It is important to emphasise that none of the hypotheses considered above are ‘new’. All have been 
advanced in the context of the current pandemic or in other infections. What is offered here is a 
formalisation of these hypotheses, and a generative model that could be used to evaluate them. In 
addition, generative models may be used to simulate interventions (e.g., pharmacological treatments) 
to try to understand what might happen before moving to more expensive or risky empirical tests. The 
generative modelling approach has been employed in the past to assess models of the immune response 
to dengue virus [62]. The authors used temporally dense measurements of viral load and antibody titre 
to fit a ‘target-cell’ model – highlighting the utility of dynamic modelling of immunity. The approach 
pursued in this paper is closely related to the target-cell approach to modelling viral infections but 
differs in a few important ways [63]. Target-cell models – in their simplest manifestation – describe the 
dynamics of an infection in much the same way Susceptible-Exposed-Infectious-Recovered (SEIR) 
models describe an epidemic. In place of the number of individuals at various stages of being infected 
by a pathogen, target-cell models deal with the number of cells infected. Our approach here differs from 
this in that it factorises the immune response into several interacting modules. This affords the 
opportunity for richer generative models which, using variational Bayes and Bayesian model reduction, 
may be inverted relatively quickly. 
It is interesting that the mechanisms of resistance illustrated here tend to flatten, as opposed to fully 
suppress, the viral load curve. This could mean one of (or some combination of) two things. A lower 
load may make someone less able to transmit the infection. Alternatively, a prolonged period of having 
a non-negligible viral load may increase the period for which they are infectious. Each of these has 
important consequences in SEIR (or LIST) epidemiological models. The former favours resistance both 
to the infection itself, and to passing it on. The latter might be more consistent with the notion of a 
super-spreader, who has an insufficient viral load to cause symptoms that would prompt testing or 
isolation but is infectious for longer.  
Clearly a major limitation of the work presented here is that it is based upon purely synthetic data. As 
such, this should be viewed as a proof-of-principle whose priors will require refinement as data from 
longitudinal studies [38] and vaccine trials become available [64]. Related to this are the temporally 
dense (daily) measurements assumed in the model fitting. In the presence of more precise prior beliefs 
derived from such studies, it should be possible to achieve posterior estimates with greater certainty and 
less data per individual. Another limitation is the relative coarseness of the immune model. There are 
many nuances that could be incorporated into a model of this sort. Relevant to the current SARS-CoV-
2 pandemic is the direct influence of the virus on T-cell populations. Some stages of the SARS-CoV-2 
infection are associated with a decrease in the functional CD8+ cell population [9] and lymphopenia 
[65]. There is precedent for thinking about targeting of lymphocytes by viral pathogens, with the most 
obvious example being the reduction in CD4 counts mediated by human immunodeficiency virus (HIV) 
[66]. However, the pattern in Covid-19 seems to be more a skew in the sorts of cells naïve T-cells 
differentiate into [67] – a viral effect on T-cell transition probabilities that could be explicitly 
parameterised using this approach. 
One possible extension to this work would be to consider separate anatomical compartments. Here, the 
same mean-field model could be replicated for different parts of the body. This would be similar to the 
connection of multiple neural mass models in neuroscience – to model effective connectivity between 
different brain regions [68] – or to connectivity between multiple LIST models as was used to model 
SARS-CoV-2 propagation between parts of the United States [3]. This would allow for modelling of 
the transfer of virus between different anatomical sites (e.g., between the nasopharynx and the lungs) 
in addition to transfer of immune cells (e.g., between lymphoid organs and the lungs) [69]. Including 
this anatomical dimension may also be of use in modelling the effect of Covid-19 on specific body 
systems, including the increasingly recognised neurological manifestations, enabling measurements in 
the cerebrospinal fluid to inform the same parameters as serological measures. However, it is worth 
noting that there is little evidence so far for cerebrospinal viral load playing a direct role in neurological 
disease [70]. 
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Finally, having discussed the translation of analysis tools from neuroscience to immunology, it is worth 
briefly considering other points of contact that could be exploited in future work. One of these is the 
importance of immunological processes in neurological disease. Another is the relationship between 
the brain and immune system in health. Regarding the former, there is an opportunity to combine 
neurobiological and immunological models. Recently, DCM for neuroimaging has been extended to 
accommodate fusion of several different imaging modalities [71]. This raises the possibility of fusing 
immunological and neurobiological DCMs, to model conditions – like multiple sclerosis [72,73] or 
autoimmune encephalitides [74] – in which the immune and nervous systems interact. Here the aim 
would be to generate both neurophysiological and immunological measurements. Given serial 
electroencephalograms and serological tests, it might be possible to measure the influence of immune 
system compartments on neural connectivity over time. 
The relationship between the nervous and immune systems in health is another important topic. Here 
there is another opportunity to translate between theoretical neurobiology and immunology. A 
prominent approach in the former is active inference, which frames the internal dynamics of the nervous 
system as solving an inference problem based upon sensory data – where these inferences direct 
behaviour through effector systems [75]. From this perspective, it suffices to define the problem being 
solved. The optimal solution emerges from identification of this problem. This has been successful in 
accounting for a range of neurophysiological and behavioural observations [76-78]. Like the nervous 
system, the immune system exhibits complex internal dynamics [69], and interfaces with foreign agents 
via (molecular) receptors and effectors. It follows that the immune system may be amenable to similar 
approaches, which could help uncover the principles from which the interactions simulated above could 
emerge. Given extensive interfaces between neural and immune tissue – both directly [79-83] and via 
the neuroendocrine system [84] – it may be possible to take this further, through identifying the problem 
that these systems jointly solve. We hope to explore this avenue of theoretical neuroimmunology in 
future work. 
 
6 – Conclusion 
Ultimately, the simulations above are not designed to draw any specific conclusions about the nature of 
‘immunological dark matter’, but to show how dynamic causal modelling could be applied to 
understand which mechanisms of resistance (i.e., attenuation of viral load) might be in play. However, 
one conclusion that can be drawn from this is the importance of not over-interpreting serological results. 
If alternative immunological phenotypes like those simulated above exist in populations affected by 
Covid-19, serological measures alone are likely to underestimate the effective immunity (or resistance) 
in the population.  We have illustrated the use of a dynamic model of immune responses to supplement 
empirical and conceptual analyses of responses to viral pathogens or vaccines. In addition, we found 
that – using synthetic data – it is possible to recover the models that generate immune responses and to 
test hypotheses about the relationship between demographic factors and parameters of these models. 
 
Software note 
The simulations presented here may be reproduced and customised using the DEM_Immune.m demo 
which will be available as part of the next public release of SPM12. This academic freeware may be 
downloaded from https://www.fil.ion.ucl.ac.uk/spm/software/spm12/.  
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